Kindred Biosciences, Inc. (KIN) financial statements (2021 and earlier)

Company profile

Business Address 1555 BAYSHORE HIGHWAY, SUITE 200
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:607474835773101
Cash and cash equivalents1216563572013
Short-term investments47561846505388
Other undisclosed cash, cash equivalents, and short-term investments22(0)1   
Receivables111    
Inventory, net of allowances, customer advances and progress billings044    
Inventory044    
Other undisclosed current assets212(1)110
Total current assets:637980825874102
Noncurrent Assets
Operating lease, right-of-use asset33
Property, plant and equipment2830267210
Long-term investments and receivables22 115 
Long-term investments22 115 
Other noncurrent assets0000000
Total noncurrent assets:3335269460
TOTAL ASSETS:96114106916280102
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities510156433
Accounts payable0141010
Accrued liabilities3482211
Employee-related liabilities2433221
Debt11     
Other undisclosed current liabilities1      
Total current liabilities:710156433
Noncurrent Liabilities
Long-term debt and lease obligation2122     
Long-term debt, excluding current maturities1919     
Operating lease, liability33
Liabilities, other than long-term debt  00000
Accounts payable and accrued liabilities  00000
Other undisclosed noncurrent liabilities(3)      
Total noncurrent liabilities:212200000
Total liabilities:2832156433
Stockholders' equity
Stockholders' equity attributable to parent, including:67829185587699
Common stock0000000
Additional paid in capital312305253197139135131
Accumulated other comprehensive income (loss)00(0)(0)(0)(0)(0)
Accumulated deficit(245)(223)(162)(112)(81)(59) 
Other undisclosed stockholders' equity attributable to parent      (31)
Total stockholders' equity:67829185587699
TOTAL LIABILITIES AND EQUITY:96114106916280102

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues4242    
Cost of revenue
(Cost of Goods and Services Sold)
(5)(1)(0)    
Gross profit:3842    
Operating expenses(58)(66)(53)(32)(23)(27)(27)
Other undisclosed operating income 00    
Operating loss:(20)(63)(51)(32)(23)(27)(27)
Nonoperating income (expense)(2)121000
Investment income, nonoperating0121000
Net loss available to common stockholders, diluted:(22)(61)(50)(31)(22)(27)(27)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(22)(61)(50)(31)(22)(27)(27)
Comprehensive loss:(22)(61)(50)(31)(22)(27)(27)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00 0(0)(0)
Comprehensive loss, net of tax, attributable to parent:(22)(61)(50)(31)(22)(27)(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: